Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Infections and infestations – page 14

  • 677 clinical trials
  • 261 recruiting
  • 278 conditions
  • 27 countries

Conditions in this area

278 conditions with trials, the busiest first

HIV infection75COVID-1939Pneumonia32Sepsis29Influenza28Respiratory syncytial virus infection20Post-acute COVID-19 syndrome19Septic shock17Urinary tract infection17Chronic hepatitis B16Bacterial infection14Hepatitis D14Cytomegalovirus infection13Appendicitis10Hepatitis B10Pneumonia bacterial10Fungal infection9Irritable bowel syndrome8Medical device site joint infection8Pyelonephritis acute7Staphylococcal bacteraemia7Staphylococcal infection7T-cell type acute leukaemia7Lower respiratory tract infection6+254

Clinical trials in Infections and infestations

677 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

677 clinical trials

Pneumonia+1

Recruiting

Study on Amoxicillin and Clavulanic Acid for Treating Ventilator-Associated Pneumonia in Intensive Care Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:Assistance Publique Hopitaux De Paris

Staphylococcal infection

Recruiting

Study Comparing Dalbavancin to Standard Antibiotics for Patients with Staphylococcus aureus Bloodstream Infections

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amikacin Sulfate
  • Sponsor:Assistance Publique Hopitaux De Paris

HIV infection

Recruiting

Study on Pomalidomide for HIV Control in Patients on ART and During Treatment Interruption

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Pomalidomide
  • Sponsor:Region Midtjylland

HIV infection

Recruiting

Study of Bictegravir and Lenacapavir for Children and Adolescents with HIV-1

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Bictegravir
  • Sponsor:Gilead Sciences Inc.

Post transplant lymphoproliferative disorder+1

Recruiting

Study of Tabelecleucel for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Transplant Treatment Failure

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tabelecleucel
  • Sponsor:Pierre Fabre Medicament

Pathogen resistance

Recruiting

Study on Piperacillin-Tazobactam and Temocillin for Treating Severe Infections in ICU Patients with ESBL-Producing Gram-Negative Bacteria

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Meropenem Anhydrous
  • Sponsor:Assistance Publique Hopitaux De Paris

Irritable bowel syndrome

Recruiting

Study on the Effects of GSL-01-001 for Patients with Irritable Bowel Syndrome (IBS) Type D

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Cannabidiol
  • Sponsor:Cannabibs Sp. z o.o.

Sepsis

Recruiting

Study on Optimizing Initial Dosing of Flucloxacillin and Drug Combination for Critically Ill Patients with Sepsis in the ICU

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Irritable bowel syndrome

Recruiting

Study on the Effectiveness and Safety of Myrrh, Coffee Charcoal, and Chamomile Extract for Patients with Diarrhea-Dominant or Mixed-Type Irritable Bowel Syndrome

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Coffee Charcoal
  • Sponsor:REPHA GmbH Biologische Arzneimittel

Epstein-Barr virus associated lymphoproliferative disorder

Recruiting

Study on Tabelecleucel for Patients with Epstein-Barr Virus-Associated Diseases

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tabelecleucel
  • Sponsor:Pierre Fabre Medicament

Irritable bowel syndrome

Recruiting

Study on the Effectiveness and Safety of Myrrh, Coffee Charcoal, and Chamomile Extract for Patients with Diarrhea-Predominant Irritable Bowel Syndrome

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Coffee Charcoal
  • Sponsor:REPHA GmbH Biologische Arzneimittel

Staphylococcal infection+1

Recruiting

Study on the Safety of Inhaled Teicoplanin for Treating Staphylococcus aureus Infections in Cystic Fibrosis Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Teicoplanin
  • Sponsor:Azienda Ospedaliera Universitaria Integrata Verona

Substances studied in this area

The therapies tested most often in Infections and infestations trials.

Sodium Chloride52 clinical trialsAmoxicillin35 clinical trialsEmtricitabine32 clinical trialsLinezolid32 clinical trialsTenofovir Alafenamide32 clinical trialsClavulanic Acid28 clinical trialsRifampicin25 clinical trialsSulfamethoxazole25 clinical trialsTrimethoprim25 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.